Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Polycystic Ovarian Syndrome: Current Situation of Female Hormonal Disorder

Author(s): Vikash Chaturvedi, Disha Sharma, Vaishnavi Pandey, Sudhanshu Mishra, Shobhit Prakash Shrivastava, Akanksha Sharma and Rishabha Malviya*

Volume 19, Issue 2, 2023

Published on: 14 June, 2022

Article ID: e080222200917 Pages: 9

DOI: 10.2174/1573404818666220208110240

Price: $65

Abstract

Aim: This study aims to describe the various concerns and treatment strategies associated with the polycystic ovarian syndrome. Polycystic syndrome of ovaries is the most prevalent endocrine problem in adult women and is distinguished by anovulation, excess androgen, and the involvement of ultrasound polycystic ovaries. Hirsutism, obesity, miscarriage, and menstrual irregularities are the signs that are particularly troubling for patients. The hypothesis describes that PCOS is a systemic disease reinforced by recent discoveries amplifying hormones and cytokines in muscle mass tissue.

Result and discussion: The treatment strategy should be adapted to the patient's phenotype, problems, and willingness to replicate. Infertility care centers on treatments for activation of ovulation and may include medications, such as metformin, letrozole, clomiphene, and gonadotropin. The application of oral contraception and the adjuvant application of anti-androgens also includes the management of hirsutism. For both treatments of infertility and long-term management, weight loss in obese women with PCOS can be helpful.

Conclusion: The literature survey concluded that the proper diagnosis and treatment of PCOS are important; otherwise, it cannot be adequately controlled and can cause many metabolic disorders and other health-related risks.

Keywords: Hormonal disorder, PCOS, hirsutism, metformin, polycystic ovary syndrome, nanoformulation.

Graphical Abstract

[1]
Rebar RW, Catherino WH. Reproductive Endocrinology and Infertility Cecil Textbook of Medicine. (25th ed.), Philadelphia, PA: Elsevier Saunders 2016.
[2]
Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metab 2018; 86: 33-43.
[http://dx.doi.org/10.1016/j.metabol.2017.09.016] [PMID: 29024702]
[3]
Rocha AL, Oliveira FR, Azevedo RC, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000 Res 2019; 8: 1-11.
[http://dx.doi.org/10.12688/f1000research.15318.1] [PMID: 31069057]
[4]
Madnani N, Khan K, Chauhan P. Parmar. Polycystic ovarian syndrome: A review. Indian J Dermatol Venereol Leprol 2014; 80(2): 154-5.
[http://dx.doi.org/10.4103/0378-6323.129399] [PMID: 24685856]
[5]
Eyvazzadeh AD, Pennington KP, Pop-Busui R, Sowers M, Zubieta JK, Smith YR. The role of the endogenous opioid system in polycystic ovary syndrome. Fertil Steril 2009; 92(1): 1-12.
[http://dx.doi.org/10.1016/j.fertnstert.2009.05.012] [PMID: 19560572]
[6]
Trikudanathan S. Polycystic ovarian syndrome. Med Clin North Am 2015; 99(1): 221-35.
[http://dx.doi.org/10.1016/j.mcna.2014.09.003] [PMID: 25456652]
[7]
Bilal M, Haseeb A, Rehman A. Relationship of polycystic ovarian syndrome with cardiovascular risk factors. Diabetes Metab Syndr 2018; 12(3): 375-80.
[http://dx.doi.org/10.1016/j.dsx.2018.01.006] [PMID: 29396250]
[8]
Tomlinson JA, Pinkney JH, Evans P, Millward A, Stenhouse E. Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome. Br J Diabetes Vasc Dis 2013; 13(3): 115-23.
[http://dx.doi.org/10.1177/1474651413495571]
[9]
Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97(1): 28-38.e25.
[http://dx.doi.org/10.1016/j.fertnstert.2011.09.024] [PMID: 22153789]
[10]
Day F, Karaderi T, Jones MR, et al. 23andMe Research Team. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 2018; 14(12): e1007813.
[http://dx.doi.org/10.1371/journal.pgen.1007813] [PMID: 30566500]
[11]
Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 2015; 36(5): 487-525.
[http://dx.doi.org/10.1210/er.2015-1018] [PMID: 26426951]
[12]
Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10(8): 2107-11.
[http://dx.doi.org/10.1093/oxfordjournals.humrep.a136243] [PMID: 8567849]
[13]
Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001; 7(4): 405-10.
[http://dx.doi.org/10.1093/humupd/7.4.405] [PMID: 11476353]
[14]
Rajkhowa M, Glass MR, Rutherford AJ, Michelmore K, Balen AH. Polycystic ovary syndrome: A risk factor for cardiovascular disease? BJOG 2000; 107(1): 11-8.
[http://dx.doi.org/10.1111/j.1471-0528.2000.tb11572.x] [PMID: 10645855]
[15]
Balen A. The pathophysiology of polycystic ovary syndrome: Trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 2004; 18(5): 685-706.
[http://dx.doi.org/10.1016/j.bpobgyn.2004.05.004] [PMID: 15380141]
[16]
Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. Am Fam Physician 2016; 94(2): 106-13.
[PMID: 27419327]
[17]
Stanger JD, Yovich JL. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol 1985; 92(4): 385-93.
[http://dx.doi.org/10.1111/j.1471-0528.1985.tb01113.x] [PMID: 3921051]
[18]
Nedresky D, Singh G. Physiology, luteinizing hormone. Treasure Island, FL: StatPearls 2019.
[19]
Smitz J, Wolfenson C, Chappel S, Ruman J. Follicle-stimulating hormone: A review of form and function in the treatment of infertility. Reprod Sci 2016; 23(6): 706-16.
[http://dx.doi.org/10.1177/1933719115607992] [PMID: 26446000]
[20]
Orlowski M, Sarao MS. Physiology, follicle stimulating hormone. Stat Pearls 2020.
[21]
Wehr E, Möller R, Horejsi R, et al. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. Wien Klin Wochenschr 2009; 121(7-8): 262-9.
[http://dx.doi.org/10.1007/s00508-009-1162-2] [PMID: 19562283]
[22]
Lerchbaum E, Schwetz V, Giuliani A, Pieber TR, Obermayer-Pietsch B. Opposing effects of DHEAS and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil Steril 2012; 98(5): 1318-25.
[http://dx.doi.org/10.1016/j.fertnstert.2012.07.1057] [PMID: 22835450]
[23]
Lerchbaum E, Schwetz V, Rabe T, Giuliani A, Obermayer-Pietsch B. Hyperandrogenemia in polycystic ovary syndrome: Exploration of the role of free testosterone and androstenedione in metabolic phenotype. PLoS One 2014; 9(10): e108263.
[http://dx.doi.org/10.1371/journal.pone.0108263] [PMID: 25310562]
[24]
Yeung TWY, Li RHW, Lee VCY, Ho PC, Ng EHY. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J Clin Endocrinol Metab 2013; 98(1): 380-8.
[http://dx.doi.org/10.1210/jc.2012-3071] [PMID: 23144466]
[25]
Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87(5): 2134-8.
[http://dx.doi.org/10.1210/jcem.87.5.8387] [PMID: 11994353]
[26]
Christodoulaki C, Trakakis E, Pergialiotis V, et al. Dehydroepiandrosterone-sulfate, insulin resistance and ovarian volume estimation in patients with polycystic ovarian syndrome. J Family Reprod Health 2017; 11(1): 24-9.
[PMID: 29114265]
[27]
Szosland K, Pawlowicz P, Lewiński A. Prolactin secretion in polycystic ovary syndrome (PCOS). Neuroendocrinol Lett 2015; 36(1): 53-8.
[PMID: 25789595]
[28]
Delcour C, Robin G, Young J, Dewailly D. PCOS and Hyperprolactinemia: What do we know in 2019? Clin Med Insights Reprod Health 2019; 13: 1179558119871921.
[http://dx.doi.org/10.1177/1179558119871921] [PMID: 31523136]
[29]
Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. Treasure Island, FL: Stat Pearls Publishing 2020.
[30]
Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004; 10(2): 107-17.
[http://dx.doi.org/10.1093/humupd/dmh010] [PMID: 15073141]
[31]
Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008; 23(4): 952-7.
[http://dx.doi.org/10.1093/humrep/den015] [PMID: 18256110]
[32]
Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity-a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004; 183(2): 331-42.
[http://dx.doi.org/10.1677/joe.1.05762] [PMID: 15531721]
[33]
Unfer V, Casini ML, Marelli G, Costabile L, Gerli S, Di Renzo GC. Different routes of progesterone administration and polycystic ovary syndrome: A review of the literature. Gynecol Endocrinol 2005; 21(2): 119-27.
[http://dx.doi.org/10.1080/09513590500170049] [PMID: 16109599]
[34]
Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine 2006; 30(1): 19-26.
[http://dx.doi.org/10.1385/ENDO:30:1:19] [PMID: 17185788]
[35]
Shannon M, Wang Y. Polycystic ovary syndrome: A common but often unrecognized condition. J Midwifery Womens Health 2012; 57(3): 221-30.
[http://dx.doi.org/10.1111/j.1542-2011.2012.00161.x] [PMID: 22594862]
[36]
Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007; 3(2): 103-11.
[http://dx.doi.org/10.1038/ncpendmet0400] [PMID: 17237837]
[37]
Marx TL, Mehta AE. Polycystic ovary syndrome: Pathogenesis and treatment over the short and long term. Cleve Clin J Med 2003; 70(1): 31-33, 36-41, 45.
[http://dx.doi.org/10.3949/ccjm.70.1.31] [PMID: 12549723]
[38]
Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: Observations from the Dallas Heart Study. J Am Coll Cardiol 2007; 49(1): 109-16.
[http://dx.doi.org/10.1016/j.jacc.2006.10.040] [PMID: 17207730]
[39]
Hsueh AJ, Kawamura K, Cheng Y, Fauser BC. Intraovarian control of early folliculogenesis. Endocr Rev 2015; 36(1): 1-24.
[http://dx.doi.org/10.1210/er.2014-1020] [PMID: 25202833]
[40]
Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008; 14(4): 367-78.
[http://dx.doi.org/10.1093/humupd/dmn015] [PMID: 18499708]
[41]
Ibáñez L, Oberfield SE, Witchel S, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017; 88(6): 371-95.
[http://dx.doi.org/10.1159/000479371] [PMID: 29156452]
[42]
Speroff L, Fritz MA. Anovulation and the polycystic ovary. In: Speroff L, Fritz MA, Eds. Philadelphia, PA: clinical gynecologic endocrinology and infertility, lippincott Williams & Wilkins 2005; pp. 470-83.
[43]
Ehrmann DA, Rychlik D. Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med 2003; 21(3): 277-83.
[http://dx.doi.org/10.1055/s-2003-43305] [PMID: 14593550]
[44]
Lakhani K, Prelevic GM, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovary syndrome, diabetes and cardiovascular disease: Risks and risk factors. J Obstet Gynaecol 2004; 24(6): 613-21.
[http://dx.doi.org/10.1080/01443610400007810] [PMID: 16147598]
[45]
Legro RS. Evaluation and treatment of polycystic ovary syndrome. 2000. Available from: MD Text.com.
[46]
Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016; 22(6): 687-708.
[http://dx.doi.org/10.1093/humupd/dmw025] [PMID: 27511809]
[47]
Jorgensen SE, Starup J, Roos J, Micic S. Studies on the mode of action of clomiphene citrate. Acta Obstet Gynecol Scand 1976; 55(4): 337-40.
[http://dx.doi.org/10.3109/00016347609158509] [PMID: 973563]
[48]
Von Hofe J, Bates GW. Ovulation induction. Obstet Gynecol Clin North Am 2015; 42(1): 27-37.
[http://dx.doi.org/10.1016/j.ogc.2014.09.007] [PMID: 25681838]
[49]
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60(9): 1577-85.
[http://dx.doi.org/10.1007/s00125-017-4342-z] [PMID: 28776086]
[50]
Muller H, Reinwein H. On the pharmacology of galegins. Arch Exp Pathol Pharmakol 1927; 125(3-4): 212-28.
[http://dx.doi.org/10.1007/BF01862957]
[51]
Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: An old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010; 162(2): 193-212.
[http://dx.doi.org/10.1530/EJE-09-0733] [PMID: 19841045]
[52]
Casper RF, Mitwally MF. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol 2011; 54(4): 685-95.
[http://dx.doi.org/10.1097/GRF.0b013e3182353d0f] [PMID: 22031258]
[53]
Guang HJ, Li F, Shi J. Letrozole for patients with polycystic ovary syndrome: A retrospective study. Medicine (Baltimore) 2018; 97(44): e13038.
[http://dx.doi.org/10.1097/MD.0000000000013038] [PMID: 30383669]
[54]
Pavone ME, Bulun SE. Clinical review: The use of aromatase inhibitors for ovulation induction and superovulation. J Clin Endocrinol Metab 2013; 98(5): 1838-44.
[http://dx.doi.org/10.1210/jc.2013-1328] [PMID: 23585659]
[55]
Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75(2): 305-9.
[http://dx.doi.org/10.1016/S0015-0282(00)01705-2] [PMID: 11172831]
[56]
Abu Hashim H, Shokeir T, Badawy A. RETRACTED: Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: A randomized controlled trial. Fertil Steril 2010; 94(4): 1405-9.
[http://dx.doi.org/10.1016/j.fertnstert.2009.07.985] [PMID: 19732888]
[57]
Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: Understanding advantages and limitations. J Hum Reprod Sci 2014; 7(3): 170-4.
[http://dx.doi.org/10.4103/0974-1208.142476] [PMID: 25395741]
[58]
Practice Committee of American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: A technical bulletin. Fertil Steril 2008; 90(5) (Suppl.): S7-S12.
[http://dx.doi.org/10.1016/j.fertnstert.2008.08.003] [PMID: 19007651]
[59]
Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81(9): 3299-306.
[PMID: 8784087]
[60]
Azziz R, Ehrmann D, Legro RS, et al. PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86(4): 1626-32.
[http://dx.doi.org/10.1210/jc.86.4.1626] [PMID: 11297595]
[61]
Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82(4): 893-902.
[http://dx.doi.org/10.1016/j.fertnstert.2004.02.127] [PMID: 15482765]
[62]
Brashier DB, Sharma AK, Dahiya N, Singh SK, Khadka A. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother 2014; 5(2): 175-8.
[http://dx.doi.org/10.4103/0976-500X.130158] [PMID: 24799830]
[63]
Berger JJ, Bates GW Jr. Optimal management of subfertility in polycystic ovary syndrome. Int J Womens Health 2014; 6: 613-21.
[PMID: 24966697]
[64]
Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018; 5: CD010287.
[http://dx.doi.org/10.1002/14651858.CD010287.pub3] [PMID: 29797697]
[65]
Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician 2009; 79(8): 671-6.
[PMID: 19405411]
[66]
Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89(8): 3835-40.
[http://dx.doi.org/10.1210/jc.2003-031737] [PMID: 15292314]
[67]
Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs 2006; 66(1): 85-109.
[http://dx.doi.org/10.2165/00003495-200666010-00005] [PMID: 16398569]
[68]
Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci 2000; 900(1): 245-52.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb06236.x] [PMID: 10818412]
[69]
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352(12): 1223-36.
[http://dx.doi.org/10.1056/NEJMra041536] [PMID: 15788499]
[70]
Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85(1): 89-94.
[http://dx.doi.org/10.1210/jc.85.1.89] [PMID: 10634370]
[71]
Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999; 141(4): 361-7.
[http://dx.doi.org/10.1530/eje.0.1410361] [PMID: 10526249]
[72]
Johnson DB, Sonthalia S. Flutamide. Stat Pearls Publishing 2020.
[73]
Salem HF, Kharshoum RM, Abou-Taleb HA, AbouTaleb HA, AbouElhassan KM. Progesterone-loaded nanosized transethosomes for vaginal permeation enhancement: formulation, statistical optimization, and clinical evaluation in anovulatory polycystic ovary syndrome. J Liposome Res 2019; 29(2): 183-94.
[http://dx.doi.org/10.1080/08982104.2018.1524483] [PMID: 30221566]
[74]
Abdulbaqi IM, Darwis Y, Khan NAK, Assi RA, Khan AA. Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine 2016; 11: 2279-304.
[http://dx.doi.org/10.2147/IJN.S105016] [PMID: 27307730]
[75]
Abuelezz NZ, Shabana ME, Abdel-Mageed HM, Rashed L, Morcos GNB. Nanocurcumin alleviates insulin resistance and pancreatic deficits in polycystic ovary syndrome rats: Insights on PI3K/AkT/mTOR and TNF-α modulations. Life Sci 2020; 256: 118003.
[http://dx.doi.org/10.1016/j.lfs.2020.118003] [PMID: 32589998]
[76]
Karami M, Salami E, Dehkordi AJ, Nadoushan MJ, Hajnorouzi A. Protective effect of silver nano particles against ovarian polycystic induced by morphine in rat. Nanomed J 2018; 3(4): 229-35.
[77]
Anbu AS, Venkatachalam P. Biological macromolecule cross linked TPP–chitosan complex: a novel nanohybrid for improved ovulatory activity against PCOS treatment in female rats. RSC Adv 2016; 6(97): 94301-13.
[http://dx.doi.org/10.1039/C6RA07228C]
[78]
Carvalho LML, Ferreira CN, Candido AL, et al. Metformin reduces total microparticles and microparticles-expressing tissue factor in women with polycystic ovary syndrome. Arch Gynecol Obstet 2017; 296(4): 617-21.
[http://dx.doi.org/10.1007/s00404-017-4471-0] [PMID: 28795250]
[79]
Cetin M, Sahin S. Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride. Drug Deliv 2016; 23(8): 2796-805.
[http://dx.doi.org/10.3109/10717544.2015.1089957] [PMID: 26394019]
[80]
Papadakis E, Sarigianni M, Tziomalos K, Mavromatidis G, Panidis D. Oral contraceptives increase platelet microparticle levels in normal-weight women with polycystic ovary syndrome. Hormones (Athens) 2020; 19(4): 565-71.
[http://dx.doi.org/10.1007/s42000-020-00182-1] [PMID: 32078734]
[81]
Javed Z, Papageorgiou M, Madden LA, et al. The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome. Endocr Connect 2020; 9(6): 563-9.
[http://dx.doi.org/10.1530/EC-20-0173] [PMID: 32449697]
[82]
Kirk RJ, Madden LA, Peart DJ, Aye MM, Atkin SL, Vince RV. Circulating endothelial microparticles reduce in concentration following an exercise programme in women with polycystic ovary syndrome. Front Endocrinol (Lausanne) 2019; 10: 200.
[http://dx.doi.org/10.3389/fendo.2019.00200] [PMID: 30984117]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy